Free Trial
→ My next big call (under $1) (From Crypto 101 Media) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Illumina, Inc. stock logo
ILMN
Illumina
$204.34
-2.5%		$249.32
$112.65
▼
$309.35
$30.90B1.462.18 million shs410,659 shs
Moderna, Inc. stock logo
MRNA
Moderna
$224.38
-3.0%		$200.18
$22.28
▼
$280.80
$90.79B1.1612.55 million shs3.89 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Illumina, Inc. stock logo
ILMN
Illumina
-1.59%+0.75%-22.72%+9.78%+71.79%
Moderna, Inc. stock logo
MRNA
Moderna
-6.97%-4.19%+6.98%+265.37%+766.15%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Illumina, Inc. stock logo
ILMN
Illumina
$204.34
-2.5%		$249.32
$112.65
▼
$309.35
$30.90B1.462.18 million shs410,659 shs
Moderna, Inc. stock logo
MRNA
Moderna
$224.38
-3.0%		$200.18
$22.28
▼
$280.80
$90.79B1.1612.55 million shs3.89 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Illumina, Inc. stock logo
ILMN
Illumina
-1.59%+0.75%-22.72%+9.78%+71.79%
Moderna, Inc. stock logo
MRNA
Moderna
-6.97%-4.19%+6.98%+265.37%+766.15%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Illumina, Inc. stock logo
ILMN
Illumina
2.37
Hold$244.2419.65% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.08
Hold$113.75-49.66% Downside

Current Analyst Ratings Breakdown

Latest ILMN and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/9/2026
Moderna, Inc. stock logo
MRNA
Moderna
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOverweight$230.00 ➝ $305.00
11/9/2026
Moderna, Inc. stock logo
MRNA
Moderna
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetNeutral$137.00 ➝ $195.00
11/2/2026
Illumina, Inc. stock logo
ILMN
Illumina
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold (C) ➝ Buy (B-)
11/2/2026
Illumina, Inc. stock logo
ILMN
Illumina
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetSell$113.00 ➝ $210.00
10/30/2026
Illumina, Inc. stock logo
ILMN
Illumina
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingUnderperform
10/30/2026
Illumina, Inc. stock logo
ILMN
Illumina
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOverweight$320.00 ➝ $300.00
10/27/2026
Moderna, Inc. stock logo
MRNA
Moderna
William Blair logo
William Blair
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeOutperform ➝ Market Perform
10/26/2026
Moderna, Inc. stock logo
MRNA
Moderna
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOverweight$167.00 ➝ $230.00
10/23/2026
Illumina, Inc. stock logo
ILMN
Illumina
Stephens logo
Stephens
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeOverweight ➝ Equal Weight$275.00
10/23/2026
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell
10/23/2026
Illumina, Inc. stock logo
ILMN
Illumina
Stephens logo
Stephens
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeOverweight ➝ Equal Weight$275.00
(Data available from 11/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Illumina, Inc. stock logo
ILMN
Illumina
$4.34B7.11$6.44 per share31.71$20.80 per share9.81
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B47.03N/AN/A$16.90 per share13.37
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Illumina, Inc. stock logo
ILMN
Illumina
$850M$5.8135.1232.872.8919.72%28.38%12.11%N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.10N/AN/AN/A-110.46%-25.79%-15.85%N/A

Latest ILMN and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2026Q3 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$1.10$0.38+$1.48$0.38$890.25 million$1.31 billion
10/29/2026Q3 2026
Illumina, Inc. stock logo
ILMN
Illumina
$1.36$1.62+$0.26$1.43$1.15 billion$1.17 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Illumina, Inc. stock logo
ILMN
Illumina
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Illumina, Inc. stock logo
ILMN
Illumina
0.57
2.63
2.05
Moderna, Inc. stock logo
MRNA
Moderna
0.52
3.62
3.47

Institutional Ownership

CompanyInstitutional Ownership
Illumina, Inc. stock logo
ILMN
Illumina
89.42%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
Illumina, Inc. stock logo
ILMN
Illumina
2.90%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Illumina, Inc. stock logo
ILMN
Illumina
8,650151.20 million146.82 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700404.62 million360.92 millionOptionable

Recent News About These Companies

Promising Biotech Stocks To Consider - November 13th
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-promising-biotech-stocks-to-consider-november-13th-2026-11-13/
Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls
 |  zacks.comhttps://www.zacks.com/stock/news/3029512/moderna-issues-cost-outlook-amid-revenue-uncertainty-stock-falls?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-3029512
Letko Brosseau & Associates Inc. Sells 551,496 Shares of Moderna, Inc. $MRNA
November 13 at 6:27 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-letko-brosseau-associates-inc-sells-551496-shares-of-moderna-inc-mrna-2026-11-13/
Brookline Capital Markets Forecasts Moderna FY2026 Earnings
November 13 at 1:43 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31194885
Moderna Sinks 7% as Analyst Day Cancer Push Brings “$4 Billion in Cash Costs in 2027”
November 12 at 5:27 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/moderna-sinks-7-analyst-day-193806051.html
The Next Chapter of mRNA
November 12 at 5:27 PM  |  time.comT
Why Is Moderna (MRNA) Joining A Global Benchmark And Publishing New Vaccine Data?
November 12 at 5:27 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/why-moderna-mrna-joining-global-191002480.html
Moderna (NASDAQ:MRNA) Stock Falls 7% - Here's Why
November 12 at 5:19 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-moderna-nasdaq-mrna-stock-falls-7-heres-why-2026-11-12/
Moderna Targets 2027 Cancer Therapy Launch, Raises 2026 Revenue Growth Outlook
November 12 at 5:13 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-moderna-targets-2027-cancer-therapy-launch-raises-2026-revenue-growth-outlook-2026-11-12/
MRNA Stock Up 3% Since Q3 Earnings Release: How to Play the Stock?
November 12 at 1:56 PM  |  zacks.comhttps://www.zacks.com/stock/news/3028961/mrna-stock-up-3-since-q3-earnings-release-how-to-play-the-stock?cid=cs-stocknewsapi-ft-analyst_blog|most_popular_stocks-3028961
Moderna Lays Out Oncology-Driven Growth Plan at 2026 Analyst Day
November 12 at 12:26 PM  |  pharmexec.comP
Moderna Raises 2026 Revenue Growth Forecast to 15%–25% and Reports Progress in Cancer Vaccine Development
November 12 at 12:26 PM  |  investorshub.advfn.comhttps://investorshub.advfn.com/market-news/article/39899/moderna-raises-2026-revenue-growth-forecast-to-15-25-and-reports-progress-in-cancer-vaccine-development
Promising Biotech Stocks To Watch Today - November 12th
November 12 at 12:14 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-promising-biotech-stocks-to-watch-today-november-12th-2026-11-12/
Why Moderna Stock Dropped on Thursday
November 12 at 12:13 PM  |  fool.comhttps://www.fool.com/investing/2026/11/12/why-moderna-stock-dropped-on-thursday/
Moderna Needs a Post-Covid Hit. Its Cancer-Drug Spending Plan Ups the Stakes.
November 12 at 10:35 AM  |  barrons.comhttps://www.barrons.com/articles/moderna-stock-covid-cancer-drug-biotech-f3865a56
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Moderna, Inc. (NASDAQ:MRNA)
November 12 at 8:00 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/congress-rep-gilbert-ray-cisneros-jr-purchases-shares-of-moderna-inc-nasdaq-mrna-2026-11-12/
Moderna, Inc.: Moderna Outlines Next Phase of Growth at Analyst Day
November 12 at 7:25 AM  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-11/70111543-moderna-inc-moderna-outlines-next-phase-of-growth-at-analyst-day-200.htm
Moderna Outlines Next Phase of Growth at Analyst Day
November 12 at 7:25 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/moderna-outlines-next-phase-growth-120000477.html
FY2029 EPS Forecast for Moderna Decreased by Analyst
November 12 at 2:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31193161
Moderna CEO: Laying ground for cancer vaccine to sell more than Keytruda
November 11 at 8:24 PM  |  bioworld.comB
Moderna Announces JAMA Network Open Publication of Real-World Comparative Effectiveness Data for mNEXSPIKE (COVID-19 Vaccine, mRNA) in Adults Aged 65 Years and Older
November 11 at 3:24 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/moderna-announces-jama-network-open-161000734.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
White Tesla sports car parked at a launch site with rocket boosters visible against a sunset sky.
Tesla's Roadster Reveal Hints at 2 Much Bigger Moves
By Sam Quirke | October 19, 2026
Salesforce cloud logo in a futuristic tech setting, highlighting CRM enterprise software and AI platform growth.
Salesforce Fuels AI Engine With $5.66B Braze Buyout
By Jeffrey Neal Johnson | October 21, 2026
Industrial energy facility with cooling units, piping systems, and a large turbine beside flowing water.
These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington
By Chris Markoch | October 18, 2026
Lemonade logo over a house graphic with icons for home, renters, car, and pet insurance, a dog and cat in the yard.
Lemonade's Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
By Thomas Hughes | November 8, 2026
Vaccine vial and syringe on a lab surface with DNA strands and virus particle illustrations in the background.
Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid?
By Chris Markoch | October 27, 2026
Illumina stock logo

Illumina NASDAQ:ILMN

$204.34 -5.21 (-2.49%)
As of 01:01 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Moderna stock logo

Moderna NASDAQ:MRNA

$224.38 -6.98 (-3.01%)
As of 01:01 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas